Literature DB >> 21285431

Bevacizumab treatment for solid tumors: boon or bust?

Daniel F Hayes.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21285431     DOI: 10.1001/jama.2011.57

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  32 in total

1.  Antiangiogenic agents: fueling cancer's hypoxic roots.

Authors:  Sarah J Conley; Max S Wicha
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

2.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Authors:  Sarah J Conley; Elizabeth Gheordunescu; Pramod Kakarala; Bryan Newman; Hasan Korkaya; Amber N Heath; Shawn G Clouthier; Max S Wicha
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 3.  Reappraising antiangiogenic therapy for breast cancer.

Authors:  Robert S Kerbel
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

4.  Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.

Authors:  Federica Cuppone; Emilio Bria; Vanja Vaccaro; Fabio Puglisi; Alessandra Fabi; Isabella Sperduti; Paolo Carlini; Michele Milella; Cecilia Nisticò; Michelangelo Russillo; Paola Papaldo; Gianluigi Ferretti; Matti Aapro; Diana Giannarelli; Francesco Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2011-05-12

Review 5.  Personalized cancer medicine--advances and socio-economic challenges.

Authors:  David B Jackson; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2011-10-11       Impact factor: 66.675

Review 6.  Bevacizumab: a review of its use in advanced cancer.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

7.  Hypoxia-Inducible Factors and Cancer.

Authors:  Jonathan C Jun; Aman Rathore; Haris Younas; Daniele Gilkes; Vsevolod Y Polotsky
Journal:  Curr Sleep Med Rep       Date:  2017-01-28

8.  Oncologic Angiogenesis Imaging in the clinic---how and why.

Authors:  Karen A Kurdziel; Liza Lindenberg; Peter L Choyke
Journal:  Imaging Med       Date:  2011-09

9.  Adenovirus-expressed preS2 antibody inhibits hepatitis B virus infection and hepatic carcinogenesis.

Authors:  Qian Zhang; Zhi-Qing Li; Hu Liu; Jia-He Yang
Journal:  World J Gastroenterol       Date:  2012-01-28       Impact factor: 5.742

Review 10.  Mouse models for studying angiogenesis and lymphangiogenesis in cancer.

Authors:  Lauri Eklund; Maija Bry; Kari Alitalo
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.